VBIV - VBI Vaccines Total Debt to Capital

The VBI Vaccines Inc. (VBIV) price chart demonstrates a total debt-to-equity ratio of 0.00. The business relies on domestic government cycles, establishing it as a defensive asset independent of global crises. An efficiency advantage in Hepatitis B vaccines allows the company to exercise pricing power. A diverse pipeline of drugs at various testing stages minimizes potential losses from regulatory decisions.

VBIV: VBI Vaccines Inc Total Debt to Capital 07/04/2022 - 08/17/2024

Analytical breakdowns for VBI Vaccines Inc.

- price and consensus price forecast:

Price Chart VBI Vaccines, Inc.|VBIV - Forecast Levels Chart

- market capitalization statistics:

Market Capitalization VBI Vaccines|VBIV - Value Adjusted for Debt and Cash

- book capitalization indicators:

Book Value per Share VBI Vaccines|VBIV - Book Capitalization|Market Value to Book Value Ratio vbivaccines.com|VBIV - Aggregate Asset Value

- company total debt and liquidity indicators:

- earnings and valuation multiples information:

VBIV - Net Financial Result

Basic company analysis:VBI Vaccines Inc.

For the investor, this ratio serves as a measure of financial stability, comparing total liabilities against equity to assess bankruptcy risks. Amid liquidity shortages at VBI Vaccines Inc. (VBIV) and costly R&D, it reveals a critical dependence on borrowed capital, which is clearly demonstrated by the shift in the business leverage ratio on the GURU.Markets platform as an indicator of the company's solvency.

Competitor analysis for VBI Vaccines Inc.